Answers are grounded in this paper and cite their sources.
Preclinical tests reveal 24 topical skin care products maintain device efficacy in patients with glioblastoma, indicating best practices for skin adverse events management.
BACKGROUND Tumor Treating Fields (TTFields) therapy is an approved treatment for glioblastoma (for newly diagnosed and recurrent), pleural mesothelioma, and metastatic non-small cell lung carcinoma. TTFields therapy is delivered to patients continuously via skin-adherent arrays, creating an inherent risk of skin irritation. To maintain patient quality-of-life and increase treatment effectiveness by preserving device usage time, proactive measures should be taken for management of skin adverse events (AEs). The goal of this study was to identify which commercially available topical skin care products may be used to alleviate device-related skin irritation without compromising treatment effectiveness. MATERIAL AND METHODS We tested the effect of topical skin care products on array adhesiveness (by measuring the force needed to peel off the array) and on electric current delivery. We selected for examination products that are recommended for preserving good skin health or are customary for the treatment of skin AEs, including skin barriers, topical corticosteroids, anti-itching products, wound healing agents, topical antimicrobials, and moisturizers. We performed a wide screen in animal models on 34 compounds, and then validated the results in healthy humans for 8 of the compounds. RESULTS The preclinical tests identified 24 compounds that did not interfere with array adhesiveness or electric current delivery, coming from the various medical use groups. The products that were determined to potentially interfere with TTFields delivery contained an electrical insulator/lipid component as the major ingredient. The human study corroborated the preclinical results. CONCLUSION To properly manage skin AEs in patients treated with TTFields therapy, topical skin care products should be selected that do not compromise TTFields delivery. This study provides a selection of such commercially available products.
No takes yet. Share an insight, caveat, or question.
Sadovnik et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: